- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Medco Research submits NDA for ViaScint
Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients
Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients undergoingcoronary artery bypass grafting (SCAN 1/17/96). Medco Research,of Research Triangle Park, NC, also developed cardiac stress agentAdenoscan, which is marketed by Fujisawa.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
